These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 8468272)

  • 1. Solid second cancers following Hodgkin's disease.
    Tucker MA
    Hematol Oncol Clin North Am; 1993 Apr; 7(2):389-400. PubMed ID: 8468272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Second malignancies in patients treated for Hodgkin's disease].
    Keresztes K; Miltényi Z; András C; Illés A
    Magy Onkol; 2002; 46(3):247-51. PubMed ID: 12368920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second malignancies following treatment for Hodgkin's disease: a Greek experience.
    Economopoulos T; Stathakis N; Alexopoulos C; Pavlidis N; Constantinidou M; Briassoulis E; Papageorgiou E; Dervenoulas J; Pappa V; Vaslamatzis M
    Haematologica; 1994; 79(3):273-6. PubMed ID: 7926979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Secondary tumors in Hodgkin's disease patients].
    Kovryzhkina TA; Il'in NV; Verbovetskaia VI; Shenderova IA; Smirnova EV
    Vopr Onkol; 2001; 47(5):626-30. PubMed ID: 11785109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term survival in Hodgkin's disease relative impact of mortality, second tumors, infection, and cardiovascular disease.
    Mauch PM; Kalish LA; Marcus KC; Shulman LN; Krill E; Tarbell NJ; Silver B; Weinstein H; Come S; Canellos GP; Coleman CN
    Cancer J Sci Am; 1995; 1(1):33-42. PubMed ID: 9166452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
    Brusamolino E; Anselmo AP; Klersy C; Santoro M; Orlandi E; Pagnucco G; Lunghi F; Maurizi-Enrici R; Baroni CD; Lazzarino M; Mandelli F; Bernasconi C
    Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study.
    Sacchi S; Marcheselli L; Bari A; Marcheselli R; Pozzi S; Luminari S; Lombardo M; Buda G; Lazzaro A; Gobbi PG; Stelitano C; Morabito F; Quarta G; Brugiatelli M
    Haematologica; 2008 Mar; 93(3):398-404. PubMed ID: 18268277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma.
    Brown JR; Yeckes H; Friedberg JW; Neuberg D; Kim H; Nadler LM; Freedman AS
    J Clin Oncol; 2005 Apr; 23(10):2208-14. PubMed ID: 15753460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Janeway lecture. Hodgkin's disease--finding the balance between cure and late effects.
    Donaldson SS; Hancock SL; Hoppe RT
    Cancer J Sci Am; 1999; 5(6):325-33. PubMed ID: 10606471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second cancers after Hodgkin's disease in childhood.
    Donaldson SS; Hancock SL
    N Engl J Med; 1996 Mar; 334(12):792-4. PubMed ID: 8592556
    [No Abstract]   [Full Text] [Related]  

  • 11. [New cancer disease after treatment of Hodgkin's disease].
    Abrahamsen JF; Andersen A; Hannisdal E; Nome O; Kvaløy SO; Høst H; Abrahamsen AF
    Tidsskr Nor Laegeforen; 1993 Sep; 113(23):2903-5. PubMed ID: 8236191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: a comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantation.
    Forrest DL; Hogge DE; Nevill TJ; Nantel SH; Barnett MJ; Shepherd JD; Sutherland HJ; Toze CL; Smith CA; Lavoie JC; Song KW; Voss NJ; Gascoyne RD; Connors JM
    J Clin Oncol; 2005 Nov; 23(31):7994-8002. PubMed ID: 16204014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Late treatment related complications of Hodgkin's disease].
    Henry-Amar M; Gisselbrecht C
    Rev Prat; 1998 May; 48(10):1092-7. PubMed ID: 9781154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second cancers following pediatric Hodgkin's disease.
    Wolden SL; Lamborn KR; Cleary SF; Tate DJ; Donaldson SS
    J Clin Oncol; 1998 Feb; 16(2):536-44. PubMed ID: 9469338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Second cancers in hematologic malignancies (epidemiologic observations from a 20-year period)].
    Jakó J; Szerafin L; Nagy P
    Orv Hetil; 2005 Mar; 146(10):461-9. PubMed ID: 15835344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of subsequent solid tumors after non-Hodgkin's lymphoma: effect of diagnostic age and time since diagnosis.
    Hemminki K; Lenner P; Sundquist J; Bermejo JL
    J Clin Oncol; 2008 Apr; 26(11):1850-7. PubMed ID: 18347006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Second cancers after treatment of Hodgkin's disease: experience at the International Database on Hodgkin's disease (IDHD)].
    Henry-Amar M
    Bull Cancer; 1992; 79(4):389-91. PubMed ID: 1421702
    [No Abstract]   [Full Text] [Related]  

  • 18. [Solid tumours after treatment for Hodgkin's disease (author's transl)].
    Unger PF; Auclerc G; Weil M; Jacquillat C
    Nouv Presse Med; 1981 Apr; 10(18):1463-7. PubMed ID: 7255119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of second primary cancers after Hodgkin's disease by type of treatment: analysis of 2846 patients in the British National Lymphoma Investigation.
    Swerdlow AJ; Douglas AJ; Hudson GV; Hudson BV; Bennett MH; MacLennan KA
    BMJ; 1992 May; 304(6835):1137-43. PubMed ID: 1392790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
    Harrison CN; Gregory W; Hudson GV; Devereux S; Goldstone AH; Hancock B; Winfield D; MacMillan AK; Hoskin P; Newland AC; Milligan D; Linch DC
    Br J Cancer; 1999 Oct; 81(3):476-83. PubMed ID: 10507773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.